<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-9-45</article-id><article-id pub-id-type="pmid">18498634</article-id><article-id pub-id-type="doi">10.1186/1471-2350-9-45</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Cauchi</surname><given-names>St&#x000e9;phane</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Stephane.Cauchi@good.ibl.fr</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Nead</surname><given-names>Kevin T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>knuf08@ufl.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Choquet</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>helene@good.ibl.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Horber</surname><given-names>Fritz</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>fritz@horber.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Potoczna</surname><given-names>Natascha</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>natascha.potoczna@horber.org</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Balkau</surname><given-names>Beverley</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>balkau@vjf.inserm.fr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Marre</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>michel.marre@bch.ap-hop-paris.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Charpentier</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>guillaume.charpentier@ch-sud-francilien.fr</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Froguel</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I7">7</xref><email>P.Froguel@imperial.ac.uk</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Meyre</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>meyre@good.ibl.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>CNRS UMR8090, Institut de Biologie de Lille, G&#x000e9;nomique et Physiologie Mol&#x000e9;culaire des Maladies M&#x000e9;taboliques, Lille, France</aff><aff id="I2"><label>2</label>Department of Surgery and Internal Medicine, Hirslanden Clinics, Bern and Zurich, Switzerland</aff><aff id="I3"><label>3</label>INSERM U780-IFR69, H&#x000f4;pital Paul Brousse, Villejuif, France</aff><aff id="I4"><label>4</label>Universit&#x000e9; Paris-Sud, Paris, France</aff><aff id="I5"><label>5</label>INSERM U695, H&#x000f4;pital Bichat, Paris, France</aff><aff id="I6"><label>6</label>H&#x000f4;pital de Corbeil, service d'endocrinologie et de diab&#x000e9;tologie, Corbeil-Essonnes, France</aff><aff id="I7"><label>7</label>Genomic Medicine, Hammersmith Hospital, Imperial College London, UK</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>22</day><month>5</month><year>2008</year></pub-date><volume>9</volume><fpage>45</fpage><lpage>45</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/9/45"/><history><date date-type="received"><day>30</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Cauchi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Cauchi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Cauchi St&#x000e9;phane Stephane.Cauchi@good.ibl.fr </dc:author><dc:title> The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 9(1): 45-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2008)9:1&#x0003c;45&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Considering that a portion of the heterogeneity amongst previous replication studies may be due to a variable proportion of obese subjects in case-control designs, we assessed the association of genetic variants with type 2 diabetes (T2D) in large groups of obese and non-obese subjects.</p></sec><sec sec-type="methods"><title>Methods</title><p>We genotyped <italic>RETN</italic>, <italic>KCNJ11</italic>, <italic>HNF4A</italic>, <italic>HNF1A</italic>, <italic>GCK</italic>, <italic>SLC30A8</italic>, <italic>ENPP1</italic>, <italic>ADIPOQ</italic>, <italic>PPARG</italic>, and <italic>TCF7L2 </italic>polymorphisms in 1,283 normoglycemic (NG) and 1,581 T2D obese individuals as well as in 3,189 NG and 1,244 T2D non-obese subjects of European descent, allowing us to examine T2D risk over a wide range of BMI.</p></sec><sec><title>Results</title><p>Amongst non-obese individuals, we observed significant T2D associations with <italic>HNF1A </italic>I27L [odds ratio (OR) = 1.14, <italic>P </italic>= 0.04], <italic>GCK </italic>-30G&#x0003e;A (OR = 1.23, <italic>P </italic>= 0.01), <italic>SLC30A8 </italic>R325W (OR = 0.87, <italic>P </italic>= 0.04), and <italic>TCF7L2 </italic>rs7903146 (OR = 1.89, <italic>P </italic>= 4.5 &#x000d7; 10<sup>-23</sup>), and non-significant associations with <italic>PPARG </italic>Pro12Ala (OR = 0.85, <italic>P </italic>= 0.14), <italic>ADIPOQ </italic>-11,377C&#x0003e;G (OR = 1.00, <italic>P </italic>= 0.97) and <italic>ENPP1 </italic>K121Q (OR = 0.99, <italic>P </italic>= 0.94). In obese subjects, associations with T2D were detected with <italic>PPARG </italic>Pro12Ala (OR = 0.73, <italic>P </italic>= 0.004), <italic>ADIPOQ </italic>-11,377C&#x0003e;G (OR = 1.26, <italic>P </italic>= 0.02), <italic>ENPP1 </italic>K121Q (OR = 1.30, <italic>P </italic>= 0.003) and <italic>TCF7L2 </italic>rs7903146 (OR = 1.30, <italic>P </italic>= 1.1 &#x000d7; 10<sup>-4</sup>), and non-significant associations with <italic>HNF1A </italic>I27L (OR = 0.96, <italic>P </italic>= 0.53), <italic>GCK </italic>-30G&#x0003e;A (OR = 1.15, <italic>P </italic>= 0.12) and <italic>SLC30A8 </italic>R325W (OR = 0.95, <italic>P </italic>= 0.44). However, a genotypic heterogeneity was only found for <italic>TCF7L2 </italic>rs7903146 (<italic>P </italic>= 3.2 &#x000d7; 10<sup>-5</sup>) and <italic>ENPP1 </italic>K121Q (<italic>P </italic>= 0.02). No association with T2D was found for <italic>KCNJ11</italic>, <italic>RETN</italic>, and <italic>HNF4A </italic>polymorphisms in non-obese or in obese individuals.</p></sec><sec><title>Conclusion</title><p>Genetic variants modulating insulin action may have an increased effect on T2D susceptibility in the presence of obesity, whereas genetic variants acting on insulin secretion may have a greater impact on T2D susceptibility in non-obese individuals.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Type 2 diabetes (T2D) is characterized by defects in both insulin sensitivity and beta-cell dysfunction [<xref ref-type="bibr" rid="B1">1</xref>]. This disease involves a complex interaction between genetic variants and environment with obesity established as a primary risk factor [<xref ref-type="bibr" rid="B2">2</xref>]. In this regard, correlations between increased body fat and insulin resistance have been reliably demonstrated [<xref ref-type="bibr" rid="B3">3</xref>]. Recently, associations between polymorphisms and T2D were shown to be modulated according to obesity status.</p><p><italic>ENPP1</italic>, <italic>ADIPOQ</italic>, <italic>PPARG </italic>and <italic>TCF7L2 </italic>single nucleotide polymorphisms (SNPs) have previously been associated with T2D [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>] and have shown variable significance amongst different classes of obesity. It has been suggested that the <italic>ENPP1 </italic>K121Q and <italic>ADIPOQ </italic>-11,391G&#x0003e;A and -11,377C&#x0003e;G variants may confer greater T2D susceptibility in obese populations [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. <italic>PPARG </italic>Pro12Ala, though controversial, was more associated with T2D amongst obese subgroups in our previous study [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Conversely, the <italic>TCF7L2 </italic>rs7903146 T allele has been shown to be more prevalent in T2D non-obese individuals compared to T2D obese subjects [<xref ref-type="bibr" rid="B7">7</xref>]. Interestingly, the variants in <italic>PPARG</italic>, <italic>ADIPOQ</italic>, and <italic>ENPP1</italic>, which elevate risk in obese populations, have been categorized as acting on insulin resistance while the <italic>TCF7L2 </italic>variant elevating risk in lean populations has been categorized as acting on insulin secretion [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. These preliminary results suggest that different genetic architectures could increase T2D susceptibility according to the presence or absence of obesity.</p><p>Based on these observations, we have chosen to confirm previous findings and evaluate additional genetic variants which have a reported effect on either insulin action (<italic>RETN </italic>-420C&#x0003e;G) [<xref ref-type="bibr" rid="B18">18</xref>] or insulin secretion (<italic>KCNJ11 </italic>E23K, <italic>HNF4A </italic>rs1884614 and rs2144908, <italic>HNF1A </italic>I27L, <italic>GCK </italic>-30G&#x0003e;A, and <italic>SLC30A8 </italic>R325W) [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B25">25</xref>] and which have previously been associated with T2D in large scale studies or meta-analysis [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. The evaluated variants were tested for their differential association with T2D in obese [1,283 normoglycemic (NG) and 1,581 T2D] and non-obese subjects (3,189 NG and 1,244 T2D) of European descent.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>All NG and T2D subjects were recruited in three different centers, two in France and one in Switzerland. The clinical characteristics of the studied groups are presented in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics and cohort distribution of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Obesity status</bold></td><td align="center"><bold>Glycemic status</bold></td><td align="left"><bold>Population</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>Sex ratio (men:women)</bold></td><td align="center"><bold>Age at examination (years)</bold></td><td align="center"><bold>BMI (kg/m<sup>2</sup>)</bold></td></tr></thead><tbody><tr><td align="center"><bold>Non-obese</bold></td><td align="center"><bold>NG</bold></td><td align="left"><bold>French case-control group</bold></td><td align="center">1,067</td><td align="center">477:590</td><td align="center">46 &#x000b1; 15</td><td align="center">24.3 &#x000b1; 3.0</td></tr><tr><td></td><td></td><td align="left"><bold>French D.E.S.I.R. cohort</bold></td><td align="center">2,122</td><td align="center">880:1,242</td><td align="center">47 &#x000b1; 10</td><td align="center">22.7 &#x000b1; 2.3</td></tr><tr><td></td><td></td><td align="left"><bold>Swiss group</bold></td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td></td><td></td><td align="left"><bold>Overall</bold></td><td align="center">3,189</td><td align="center">1357:1832</td><td align="center">47 &#x000b1; 12</td><td align="center">23.3 &#x000b1; 2.6</td></tr><tr><td></td><td align="center"><bold>T2D</bold></td><td align="left"><bold>French case-control group</bold></td><td align="center">1,244</td><td align="center">805:439</td><td align="center">60 &#x000b1; 11</td><td align="center">26.2 &#x000b1; 2.6</td></tr><tr><td></td><td></td><td align="left"><bold>French D.E.S.I.R. cohort</bold></td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td></td><td></td><td align="left"><bold>Swiss group</bold></td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td></td><td></td><td align="left"><bold>Overall</bold></td><td align="center">1,244</td><td align="center">805:439</td><td align="center">60 &#x000b1; 11</td><td align="center">26.2 &#x000b1; 2.6</td></tr><tr><td align="center"><bold>Obese</bold></td><td align="center"><bold>NG</bold></td><td align="left"><bold>French case-control group</bold></td><td align="center">678</td><td align="center">181:497</td><td align="center">41 &#x000b1; 11</td><td align="center">41.0 &#x000b1; 8.2</td></tr><tr><td></td><td></td><td align="left"><bold>French D.E.S.I.R. cohort</bold></td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td></td><td></td><td align="left"><bold>Swiss group</bold></td><td align="center">605</td><td align="center">128:477</td><td align="center">42 &#x000b1; 10</td><td align="center">43.7 &#x000b1; 7.0</td></tr><tr><td></td><td></td><td align="left"><bold>Overall</bold></td><td align="center">1,283</td><td align="center">309:974</td><td align="center">42 &#x000b1; 11</td><td align="center">42.2 &#x000b1; 7.8</td></tr><tr><td></td><td align="center"><bold>T2D</bold></td><td align="left"><bold>French case-control group</bold></td><td align="center">1,347</td><td align="center">645:702</td><td align="center">56 &#x000b1; 11</td><td align="center">36.8 &#x000b1; 7.1</td></tr><tr><td></td><td></td><td align="left"><bold>French D.E.S.I.R. cohort</bold></td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td></td><td></td><td align="left"><bold>Swiss group</bold></td><td align="center">234</td><td align="center">66:168</td><td align="center">46 &#x000b1; 11</td><td align="center">42.7 &#x000b1; 7.2</td></tr><tr><td></td><td></td><td align="left"><bold>Overall</bold></td><td align="center">1,581</td><td align="center">711:870</td><td align="center">54 &#x000b1; 12</td><td align="center">37.1 &#x000b1; 7.4</td></tr></tbody></table><table-wrap-foot><p><italic>P</italic>-values are from linear regression models adjusted for gender and age</p><p>NG: Normoglycemic</p><p>T2D: Type 2 Diabetic</p><p>na: Not available</p><p>Non-obese: BMI &#x0003c; 30 kg/m<sup>2</sup></p><p>Obese: BMI &#x02265; 30 kg/m<sup>2</sup></p><p>Age and BMI data presented as 'mean &#x000b1; standard deviation'</p></table-wrap-foot></table-wrap><p>Unrelated NG and T2D French white adults were recruited using a multimedia campaign run by the "Centre National de la Recherche Scientifique" (CNRS), the Department of Nutrition of the Paris H&#x000f4;tel-Dieu Hospital and the Pasteur Institute of Lille.</p><p>Individuals both non-obese and NG (n = 2,122) of the French general population, aged between 30 and 65 years, participated in the cohort for the Data From an Epidemiological Study on the Insulin Resistance syndrome (D.E.S.I.R.), a 9-year follow-up study that aims to clarify the development of the insulin resistance syndrome and described previously [<xref ref-type="bibr" rid="B31">31</xref>]. Ethnic origin cannot be legally documented in France. We estimated the proportion of subjects having non-European ancestry from a subgroup of 654 subjects selected in the D.E.S.I.R. cohort, as previously described [<xref ref-type="bibr" rid="B32">32</xref>]. We genotyped 328 SNPs which were spaced by at least 5 Mb and highly differentiated among individuals from different continents (Fst &#x0003e; 0.2 based on the Perlegen dataset) [<xref ref-type="bibr" rid="B33">33</xref>]. Analysis using the STRUCTURE software identified only two individuals of non-european ancestry in a total of 654 individuals. From this analysis, the proportion of subjects having non-European ancestry was estimated to be 0.30% in the D.E.S.I.R. cohort. Additionally, all individuals born outside France were excluded from the study.</p><p>All NG and T2D Swiss white obese individuals were from Bern and Zurich as described previously [<xref ref-type="bibr" rid="B34">34</xref>]. They were added to the French samples of the same corpulence category. No heterogeneities were found between these two population groups for all SNPs [see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>].</p><p>In all centers, two classes of glycemic status were defined according to the 1997 American Diabetes Association criteria: NG, defined as fasting glucose &#x0003c; 6.1 mmol/l and T2D, defined as fasting plasma glucose &#x02265; 7.0 mmol/l. Two separate BMI categories were analyzed in this study, according to WHO international classification: non-obese (BMI &#x0003c; 30 kg/m<sup>2</sup>), and obese (BMI &#x02265; 30 kg/m<sup>2</sup>).</p><p>This genetic study was approved by the Ethical Committee of Hotel-Dieu in Corbeil-Essonnes and CHRU in Lille and informed consent was obtained from all participants.</p></sec><sec><title>SNP genotyping</title><p>High-throughput genotyping of all genetic variants was performed using the TaqMan<sup>&#x000ae; </sup>SNP Genotyping Assays (Applied Biosystems, Foster City, Calif. USA). The PCR primers and TaqMan probes were designed by Primer Express and optimized according to the manufacturer's protocol. There was a 96&#x02013;99% genotyping success rate for all SNPs and the genotyping error rate was assessed by randomly genotyping 384 control and 384 T2D individuals. No difference was found from the first genotyping results, thus the genotyping error rate was 0% for each SNP. The genotypic distributions for all SNPs were in Hardy-Weinberg equilibrium (P &#x02265; 0.01) [see Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>].</p></sec><sec><title>Statistical analysis</title><p>The association with T2D was calculated using a logistic regression model adjusted for age, gender, and BMI. The minimum detectable effect size with a statistical power of 80% was assessed using Quanto [see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>]. The Woolf test was applied to asses the genotypic heterogeneity between obese and non-obese groups. No Bonferroni correction was applied as, in the case of replication studies, it is unlikely to detect effects due to statistical fluctuation only. All <italic>P </italic>values are two-sided. SPSS (version 14.0.2) and R statistics (version 2.5.0) software were used for general statistics.</p></sec></sec><sec><title>Results</title><p>All SNPs were evaluated for their contribution to T2D in the complete sample population (4,472 NG and 2,825 T2D), then in obese individuals (1,283 NG and 1,581 T2D) and non-obese subjects (3,189 NG and 1,244 T2D). Clinical characteristics and allelic distributions of the study population are summarized in Table <xref ref-type="table" rid="T1">1</xref> and Table <xref ref-type="table" rid="T2">2</xref>, respectively. The best fitting genetic models were selected from previous studies [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B35">35</xref>] and were in agreement with what we found in our analyses (data not shown).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Genotypic distributions in obese and non-obese subjects by glycemic status</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="6"><bold>Non-obese</bold></td><td align="center" colspan="6"><bold>Obese</bold></td></tr><tr><td></td><td></td><td colspan="12"><hr></hr></td></tr><tr><td align="center"><bold>Gene</bold></td><td align="center"><bold>SNP</bold></td><td align="center" colspan="2"><bold>Genotype 1-1</bold></td><td align="center" colspan="2"><bold>Genotype 1-2</bold></td><td align="center" colspan="2"><bold>Genotype 2-2</bold></td><td align="center" colspan="2"><bold>Genotype 1-1</bold></td><td align="center" colspan="2"><bold>Genotype 1-2</bold></td><td align="center" colspan="2"><bold>Genotype 2-2</bold></td></tr><tr><td></td><td></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td></tr></thead><tbody><tr><td align="left"><italic>ADIPOQ</italic></td><td align="left">rs17300539</td><td align="left"><bold>0.82 </bold><sub>(1,011)</sub></td><td align="left"><bold>0.82 </bold><sub>(2,579)</sub></td><td align="left"><bold>0.16 </bold><sub>(199)</sub></td><td align="left"><bold>0.17 </bold><sub>(541)</sub></td><td align="left"><bold>0.01 </bold><sub>(16)</sub></td><td align="left"><bold>0.01 </bold><sub>(37)</sub></td><td align="left"><bold>0.81 </bold><sub>(1238)</sub></td><td align="left"><bold>0.84 </bold><sub>(1059)</sub></td><td align="left"><bold>0.18 </bold><sub>(274)</sub></td><td align="left"><bold>0.15 </bold><sub>(189)</sub></td><td align="left"><bold>0.01 </bold><sub>(15)</sub></td><td align="left"><bold>0.01 </bold><sub>(15)</sub></td></tr><tr><td align="left"><italic>ADIPOQ</italic></td><td align="left">rs266729</td><td align="left"><bold>0.56 </bold><sub>(682)</sub></td><td align="left"><bold>0.56 </bold><sub>(1,753)</sub></td><td align="left"><bold>0.38 </bold><sub>(461)</sub></td><td align="left"><bold>0.37 </bold><sub>(1164)</sub></td><td align="left"><bold>0.07 </bold><sub>(83)</sub></td><td align="left"><bold>0.07 </bold><sub>(228)</sub></td><td align="left"><bold>0.55 </bold><sub>(860)</sub></td><td align="left"><bold>0.6 </bold><sub>(761)</sub></td><td align="left"><bold>0.39 </bold><sub>(611)</sub></td><td align="left"><bold>0.33 </bold><sub>(425)</sub></td><td align="left"><bold>0.06 </bold><sub>(89)</sub></td><td align="left"><bold>0.07 </bold><sub>(85)</sub></td></tr><tr><td align="left"><italic>ENPP1</italic></td><td align="left">rs1044498</td><td align="left"><bold>0.73 </bold><sub>(893)</sub></td><td align="left"><bold>0.72 </bold><sub>(2,227)</sub></td><td align="left"><bold>0.25 </bold><sub>(308)</sub></td><td align="left"><bold>0.25 </bold><sub>(785)</sub></td><td align="left"><bold>0.02 </bold><sub>(29)</sub></td><td align="left"><bold>0.03 </bold><sub>(79)</sub></td><td align="left"><bold>0.7 </bold><sub>(1086)</sub></td><td align="left"><bold>0.74 </bold><sub>(917)</sub></td><td align="left"><bold>0.27 </bold><sub>(414)</sub></td><td align="left"><bold>0.23 </bold><sub>(286)</sub></td><td align="left"><bold>0.03 </bold><sub>(53)</sub></td><td align="left"><bold>0.03 </bold><sub>(32)</sub></td></tr><tr><td align="left"><italic>PPARG</italic></td><td align="left">rs1801282</td><td align="left"><bold>0.82 </bold><sub>(1010)</sub></td><td align="left"><bold>0.79 </bold><sub>(2498)</sub></td><td align="left"><bold>0.17 </bold><sub>(209)</sub></td><td align="left"><bold>0.2 </bold><sub>(638)</sub></td><td align="left"><bold>0.01 </bold><sub>(9)</sub></td><td align="left"><bold>0.01 </bold><sub>(30)</sub></td><td align="left"><bold>0.81 </bold><sub>(1232)</sub></td><td align="left"><bold>0.76 </bold><sub>(920)</sub></td><td align="left"><bold>0.18 </bold><sub>(270)</sub></td><td align="left"><bold>0.22 </bold><sub>(270)</sub></td><td align="left"><bold>0.01 </bold><sub>(19)</sub></td><td align="left"><bold>0.02 </bold><sub>(20)</sub></td></tr><tr><td align="left"><italic>RETN</italic></td><td align="left">rs1862513</td><td align="left"><bold>0.48 </bold><sub>(590)</sub></td><td align="left"><bold>0.49 </bold><sub>(1499)</sub></td><td align="left"><bold>0.43 </bold><sub>(533)</sub></td><td align="left"><bold>0.41 </bold><sub>(1249)</sub></td><td align="left"><bold>0.09 </bold><sub>(107)</sub></td><td align="left"><bold>0.1 </bold><sub>(291)</sub></td><td align="left"><bold>0.5 </bold><sub>(775)</sub></td><td align="left"><bold>0.48 </bold><sub>(572)</sub></td><td align="left"><bold>0.4 </bold><sub>(626)</sub></td><td align="left"><bold>0.44 </bold><sub>(530)</sub></td><td align="left"><bold>0.1 </bold><sub>(150)</sub></td><td align="left"><bold>0.08 </bold><sub>(102)</sub></td></tr><tr><td align="left"><italic>GCK</italic></td><td align="left">rs1799884</td><td align="left"><bold>0.64 </bold><sub>(747)</sub></td><td align="left"><bold>0.68 </bold><sub>(2045)</sub></td><td align="left"><bold>0.32 </bold><sub>(369)</sub></td><td align="left"><bold>0.29 </bold><sub>(858)</sub></td><td align="left"><bold>0.04 </bold><sub>(48)</sub></td><td align="left"><bold>0.03 </bold><sub>(97)</sub></td><td align="left"><bold>0.65 </bold><sub>(960)</sub></td><td align="left"><bold>0.67 </bold><sub>(775)</sub></td><td align="left"><bold>0.32 </bold><sub>(466)</sub></td><td align="left"><bold>0.3 </bold><sub>(347)</sub></td><td align="left"><bold>0.03 </bold><sub>(47)</sub></td><td align="left"><bold>0.03 </bold><sub>(37)</sub></td></tr><tr><td align="left"><italic>HNF1A</italic></td><td align="left">rs1169288</td><td align="left"><bold>0.44 </bold><sub>(532)</sub></td><td align="left"><bold>0.47 </bold><sub>(1373)</sub></td><td align="left"><bold>0.44 </bold><sub>(539)</sub></td><td align="left"><bold>0.43 </bold><sub>(1270)</sub></td><td align="left"><bold>0.12 </bold><sub>(151)</sub></td><td align="left"><bold>0.1 </bold><sub>(295)</sub></td><td align="left"><bold>0.47 </bold><sub>(718)</sub></td><td align="left"><bold>0.44 </bold><sub>(537)</sub></td><td align="left"><bold>0.43 </bold><sub>(658)</sub></td><td align="left"><bold>0.44 </bold><sub>(538)</sub></td><td align="left"><bold>0.11 </bold><sub>(168)</sub></td><td align="left"><bold>0.12 </bold><sub>(143)</sub></td></tr><tr><td align="left"><italic>HNF4A</italic></td><td align="left">rs1884614</td><td align="left"><bold>0.68 </bold><sub>(840)</sub></td><td align="left"><bold>0.69 </bold><sub>(2163)</sub></td><td align="left"><bold>0.29 </bold><sub>(354)</sub></td><td align="left"><bold>0.28 </bold><sub>(873)</sub></td><td align="left"><bold>0.03 </bold><sub>(35)</sub></td><td align="left"><bold>0.03 </bold><sub>(87)</sub></td><td align="left"><bold>0.7 </bold><sub>(1078)</sub></td><td align="left"><bold>0.69 </bold><sub>(825)</sub></td><td align="left"><bold>0.28 </bold><sub>(429)</sub></td><td align="left"><bold>0.28 </bold><sub>(340)</sub></td><td align="left"><bold>0.03 </bold><sub>(44)</sub></td><td align="left"><bold>0.03 </bold><sub>(31)</sub></td></tr><tr><td align="left"><italic>HNF4A</italic></td><td align="left">rs2144908</td><td align="left"><bold>0.68 </bold><sub>(814)</sub></td><td align="left"><bold>0.69 </bold><sub>(2153)</sub></td><td align="left"><bold>0.3 </bold><sub>(355)</sub></td><td align="left"><bold>0.28 </bold><sub>(873)</sub></td><td align="left"><bold>0.03 </bold><sub>(34)</sub></td><td align="left"><bold>0.03 </bold><sub>(91)</sub></td><td align="left"><bold>0.69 </bold><sub>(1051)</sub></td><td align="left"><bold>0.68 </bold><sub>(811)</sub></td><td align="left"><bold>0.28 </bold><sub>(429)</sub></td><td align="left"><bold>0.29 </bold><sub>(348)</sub></td><td align="left"><bold>0.03 </bold><sub>(43)</sub></td><td align="left"><bold>0.03 </bold><sub>(31)</sub></td></tr><tr><td align="left"><italic>KCNJ11</italic></td><td align="left">rs5219</td><td align="left"><bold>0.41 </bold><sub>(489)</sub></td><td align="left"><bold>0.38 </bold><sub>(1145)</sub></td><td align="left"><bold>0.45 </bold><sub>(537)</sub></td><td align="left"><bold>0.48 </bold><sub>(1438)</sub></td><td align="left"><bold>0.15 </bold><sub>(180)</sub></td><td align="left"><bold>0.15 </bold><sub>(439)</sub></td><td align="left"><bold>0.41 </bold><sub>(623)</sub></td><td align="left"><bold>0.4 </bold><sub>(480)</sub></td><td align="left"><bold>0.45 </bold><sub>(683)</sub></td><td align="left"><bold>0.47 </bold><sub>(568)</sub></td><td align="left"><bold>0.15 </bold><sub>(222)</sub></td><td align="left"><bold>0.14 </bold><sub>(164)</sub></td></tr><tr><td align="left"><italic>SLC30A8</italic></td><td align="left">rs13266634</td><td align="left"><bold>0.55 </bold><sub>(661)</sub></td><td align="left"><bold>0.49 </bold><sub>(1497)</sub></td><td align="left"><bold>0.38 </bold><sub>(455)</sub></td><td align="left"><bold>0.42 </bold><sub>(1264)</sub></td><td align="left"><bold>0.08 </bold><sub>(94)</sub></td><td align="left"><bold>0.09 </bold><sub>(275)</sub></td><td align="left"><bold>0.53 </bold><sub>(792)</sub></td><td align="left"><bold>0.51 </bold><sub>(617)</sub></td><td align="left"><bold>0.4 </bold><sub>(599)</sub></td><td align="left"><bold>0.42 </bold><sub>(509)</sub></td><td align="left"><bold>0.08 </bold><sub>(114)</sub></td><td align="left"><bold>0.08 </bold><sub>(93)</sub></td></tr><tr><td align="left"><italic>TCF7L2</italic></td><td align="left">rs7903146</td><td align="left"><bold>0.3 </bold><sub>(366)</sub></td><td align="left"><bold>0.48 </bold><sub>(1,512)</sub></td><td align="left"><bold>0.5 </bold><sub>(607)</sub></td><td align="left"><bold>0.42 </bold><sub>(1326)</sub></td><td align="left"><bold>0.2 </bold><sub>(243)</sub></td><td align="left"><bold>0.09 </bold><sub>(290)</sub></td><td align="left"><bold>0.41 </bold><sub>(626)</sub></td><td align="left"><bold>0.5 </bold><sub>(614)</sub></td><td align="left"><bold>0.46 </bold><sub>(715)</sub></td><td align="left"><bold>0.41 </bold><sub>(502)</sub></td><td align="left"><bold>0.13 </bold><sub>(203)</sub></td><td align="left"><bold>0.1 </bold><sub>(119)</sub></td></tr></tbody></table><table-wrap-foot><p>Data presented as Frequency (n)</p><p>T2D: Type 2 diabetic</p><p>NG: Normoglycemic</p><p>Non-obese: BMI &#x0003c; 30 kg/m<sup>2</sup></p><p>Obese: BMI &#x02265; 30 kg/m<sup>2</sup></p><p>1: Major allele</p><p>2: Minor allele</p></table-wrap-foot></table-wrap><sec><title>All NG and T2D Individuals</title><p>We first evaluated the genetic variants amongst all NG and T2D individuals regardless of obesity status (Table <xref ref-type="table" rid="T3">3</xref>). As previously reported in a more modestly-sized French set, T2D associations were confirmed in <italic>PPARG </italic>Pro12Ala [odds ratio (OR) = 0.81, <italic>P </italic>= 0.004], <italic>TCF7L2 </italic>rs7903146 (OR = 1.59, <italic>P </italic>= 7.9 &#x000d7; 10<sup>-27</sup>), and <italic>ENPP1 </italic>K121Q (OR = 1.15, <italic>P </italic>= 0.01) [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Additionally, <italic>GCK </italic>-30G&#x0003e;A (OR 1.20, <italic>P </italic>= 0.001) and <italic>SLC30A8 </italic>R325W (OR = 0.91, <italic>P </italic>= 0.03) were also found to increase T2D risk.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Type 2 diabetes case-control study by obesity status</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Functional relevance</bold></td><td align="center"><bold>Gene name</bold></td><td align="center"><bold>SNP rs ID</bold></td><td align="center"><bold>Genetic model</bold></td><td align="center"><bold>Obesity status</bold></td><td align="center"><bold>OR [95%CI]</bold></td><td align="center"><bold><italic>P </italic>value</bold></td><td align="center"><bold>Woolf test</bold></td><td align="center" colspan="2"><bold>Risk allele frequency</bold></td></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center"><bold>T2D</bold></td><td align="center"><bold>NG</bold></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="center"><bold>Insulin action</bold></td><td align="center"><bold><italic>ADIPOQ</italic></bold></td><td align="center">rs17300539</td><td align="center">Dominant</td><td align="center">Non-obese</td><td align="center">0.96 [0.77&#x02013;1.20]</td><td align="center">0.71</td><td align="center">0.5</td><td align="center">0.09</td><td align="center">0.10</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">1.07 [0.84&#x02013;1.35]</td><td align="center">0.58</td><td></td><td align="center">0.10</td><td align="center">0.09</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">0.99 [0.86&#x02013;1.15]</td><td align="center">0.91</td><td></td><td align="center">0.10</td><td align="center">0.09</td></tr><tr><td></td><td align="center"><bold><italic>ADIPOQ</italic></bold></td><td align="center">rs266729</td><td align="center">Dominant</td><td align="center">Non-obese</td><td align="center">1.00 [0.85&#x02013;1.19]</td><td align="center">0.97</td><td align="center">0.07</td><td align="center">0.26</td><td align="center">0.26</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center"><bold>1.25 [1.04&#x02013;1.49]</bold></td><td align="center"><bold>0.015</bold></td><td></td><td align="center">0.25</td><td align="center">0.24</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">1.08 [0.96&#x02013;1.21]</td><td align="center">0.18</td><td></td><td align="center">0.25</td><td align="center">0.25</td></tr><tr><td></td><td align="center"><bold><italic>ENPP1</italic></bold></td><td align="center">rs1044498</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center">0.99 [0.84&#x02013;1.17]</td><td align="center">0.94</td><td align="center"><bold>0.02</bold></td><td align="center">0.15</td><td align="center">0.15</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center"><bold>1.30 [1.10&#x02013;1.54]</bold></td><td align="center"><bold>0.003</bold></td><td></td><td align="center">0.17</td><td align="center">0.14</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center"><bold>1.15 [1.03&#x02013;1.28]</bold></td><td align="center"><bold>0.014</bold></td><td></td><td align="center">0.16</td><td align="center">0.15</td></tr><tr><td></td><td align="center"><bold><italic>PPARG</italic></bold></td><td align="center">rs1801282</td><td align="center">Recessive</td><td align="center">Non-obese</td><td align="center">0.85 [0.69&#x02013;1.05]</td><td align="center">0.136</td><td align="center">0.24</td><td align="center">0.91</td><td align="center">0.89</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center"><bold>0.73 [0.58&#x02013;0.90]</bold></td><td align="center"><bold>0.004</bold></td><td></td><td align="center">0.90</td><td align="center">0.87</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center"><bold>0.81 [0.71&#x02013;0.94]</bold></td><td align="center"><bold>0.004</bold></td><td></td><td align="center">0.90</td><td align="center">0.89</td></tr><tr><td></td><td align="center"><bold><italic>RETN</italic></bold></td><td align="center">rs1862513</td><td align="center">Recessive</td><td align="center">Non-obese</td><td align="center">0.81 [0.60&#x02013;1.09]</td><td align="center">0.16</td><td align="center">0.11</td><td align="center">0.30</td><td align="center">0.30</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">1.14 [0.84&#x02013;1.55]</td><td align="center">0.42</td><td></td><td align="center">0.30</td><td align="center">0.31</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">1.00 [0.82&#x02013;1.22]</td><td align="center">0.99</td><td></td><td align="center">0.30</td><td align="center">0.30</td></tr><tr><td align="center"><bold>Beta-cell defect</bold></td><td align="center"><bold><italic>GCK</italic></bold></td><td align="center">rs1799884</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center"><bold>1.23 [1.06&#x02013;1.45]</bold></td><td align="center"><bold>0.009</bold></td><td align="center">0.55</td><td align="center">0.20</td><td align="center">0.17</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">1.15 [0.97&#x02013;1.35]</td><td align="center">0.12</td><td></td><td align="center">0.19</td><td align="center">0.18</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center"><bold>1.20 [1.08&#x02013;1.34]</bold></td><td align="center"><bold>0.001</bold></td><td></td><td align="center">0.19</td><td align="center">0.18</td></tr><tr><td></td><td align="center"><bold><italic>HNF1A</italic></bold></td><td align="center">rs1169288</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center"><bold>1.14 [1.01&#x02013;1.30]</bold></td><td align="center"><bold>0.042</bold></td><td align="center">0.06</td><td align="center">0.34</td><td align="center">0.32</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">0.96 [0.84&#x02013;1.10]</td><td align="center">0.53</td><td></td><td align="center">0.32</td><td align="center">0.34</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">1.02 [0.93&#x02013;1.11]</td><td align="center">0.71</td><td></td><td align="center">0.33</td><td align="center">0.32</td></tr><tr><td></td><td align="center"><bold><italic>HNF4A</italic></bold></td><td align="center">rs1884614</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center">1.06 [0.90&#x02013;1.24]</td><td align="center">0.51</td><td align="center">0.94</td><td align="center">0.17</td><td align="center">0.17</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">1.05 [0.89&#x02013;1.25]</td><td align="center">0.54</td><td></td><td align="center">0.17</td><td align="center">0.17</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">1.03 [0.93&#x02013;1.15]</td><td align="center">0.58</td><td></td><td align="center">0.17</td><td align="center">0.17</td></tr><tr><td></td><td align="center"><bold><italic>HNF4A</italic></bold></td><td align="center">rs2144908</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center">1.08 [0.92&#x02013;1.27]</td><td align="center">0.33</td><td align="center">0.75</td><td align="center">0.18</td><td align="center">0.17</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">1.04 [0.88&#x02013;1.24]</td><td align="center">0.63</td><td></td><td align="center">0.17</td><td align="center">0.17</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">1.04 [0.94&#x02013;1.16]</td><td align="center">0.45</td><td></td><td align="center">0.17</td><td align="center">0.17</td></tr><tr><td></td><td align="center"><bold><italic>KCNJ11</italic></bold></td><td align="center">rs5219</td><td align="center">Dominant</td><td align="center">Non-obese</td><td align="center">0.93 [0.78&#x02013;1.10]</td><td align="center">0.38</td><td align="center">0.8</td><td align="center">0.37</td><td align="center">0.38</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">0.96 [0.80&#x02013;1.15]</td><td align="center">0.68</td><td></td><td align="center">0.37</td><td align="center">0.37</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center">0.90 [0.80&#x02013;1.01]</td><td align="center">0.085</td><td></td><td align="center">0.37</td><td align="center">0.38</td></tr><tr><td></td><td align="center"><bold><italic>SLC30A8</italic></bold></td><td align="center">rs13266634</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center"><bold>0.87 [0.76&#x02013;0.99]</bold></td><td align="center"><bold>0.043</bold></td><td align="center">0.37</td><td align="center">0.73</td><td align="center">0.70</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center">0.95 [0.82&#x02013;1.09]</td><td align="center">0.44</td><td></td><td align="center">0.73</td><td align="center">0.71</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center"><bold>0.91 [0.83&#x02013;0.99]</bold></td><td align="center"><bold>0.033</bold></td><td></td><td align="center">0.73</td><td align="center">0.70</td></tr><tr><td></td><td align="center"><bold><italic>TCF7L2</italic></bold></td><td align="center">rs7903146</td><td align="center">Additive</td><td align="center">Non-obese</td><td align="center"><bold>1.89 [1.67&#x02013;2.14]</bold></td><td align="center"><bold>4.5 &#x000d7; 10</bold><sup>-23</sup></td><td align="center"><bold>3.2 &#x000d7; 10</bold><sup>-5</sup></td><td align="center">0.45</td><td align="center">0.30</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Obese</td><td align="center"><bold>1.30 [1.14&#x02013;1.48]</bold></td><td align="center"><bold>1.1 &#x000d7; 10</bold><sup>-4</sup></td><td></td><td align="center">0.36</td><td align="center">0.30</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">All together</td><td align="center"><bold>1.59 [1.46&#x02013;1.73]</bold></td><td align="center"><bold>7.9 &#x000d7; 10</bold><sup>-27</sup></td><td></td><td align="center">0.40</td><td align="center">0.30</td></tr></tbody></table><table-wrap-foot><p>Odds ratios were adjusted for age, gender and BMI</p><p>Woolf test: Test for heterogeneity in genotypic distribution between obese and non-obese subjects</p><p>Non-obese: BMI &#x0003c; 30 kg/m<sup>2</sup></p><p>Obese: BMI &#x02265; 30 kg/m<sup>2</sup></p></table-wrap-foot></table-wrap><p>In contrast, in our whole sample analysis, no evidence for association with T2D was found for the <italic>ADIPOQ </italic>variants -11,391G&#x0003e;A (OR = 0.99, <italic>P </italic>= 0.91) and -11,377C&#x0003e;G (OR = 1.08, <italic>P </italic>= 0.18), <italic>HNF1A </italic>I27L (OR = 1.01, <italic>P </italic>= 0.71), <italic>HNF4A </italic>variants rs1884614 (OR = 1.03, <italic>P </italic>= 0.58) and rs2144908 (OR = 1.04, <italic>P </italic>= 0.45), <italic>KCNJ11 </italic>E23K (OR = 0.9, <italic>P </italic>= 0.09), or <italic>RETN </italic>-420C&#x0003e;G (OR = 1.00, <italic>P </italic>= 0.99).</p></sec><sec><title>Non-Obese T2D Association</title><p>We then assessed the genetic variants amongst the non-obese population (BMI &#x0003c; 30 kg/m<sup>2</sup>) (Table <xref ref-type="table" rid="T3">3</xref>). The risk alleles of <italic>HNF1A </italic>I27L (OR = 1.14, <italic>P </italic>= 0.04), <italic>GCK </italic>-30G&#x0003e;A (OR = 1.23, <italic>P </italic>= 0.01), <italic>SLC30A8 </italic>R325W (OR = 0.87, <italic>P </italic>= 0.04), and <italic>TCF7L2 </italic>rs7903146 (OR = 1.89, <italic>P </italic>= 4.5 &#x000d7; 10<sup>-23</sup>) conferred a significantly increased risk of T2D.</p><p>The <italic>ADIPOQ </italic>variants -11,391G&#x0003e;A (OR = 0.96, <italic>P </italic>= 0.71) and -11,377C&#x0003e;G (OR = 1.00, <italic>P </italic>= 0.97), <italic>ENPP1 </italic>K121Q (OR = 0.99, <italic>P </italic>= 0.94), <italic>PPARG </italic>Pro12Ala (OR = 0.85, <italic>P </italic>= 0.14), <italic>RETN </italic>-420C&#x0003e;G (OR = 0.41, <italic>P </italic>= 0.14), <italic>KCNJ11 </italic>E23K (OR = 0.96, <italic>P </italic>= 0.68), and <italic>HNF4A </italic>variants rs1884614 (OR = 1.05, <italic>P </italic>= 0.54) and rs2144908 (OR = 1.08, <italic>P </italic>= 0.33) were not associated with T2D amongst the non-obese group.</p></sec><sec><title>Obese T2D Association</title><p>In the obese group (BMI &#x02265; 30 kg/m<sup>2</sup>), associations with T2D were detected in <italic>PPARG </italic>Pro12Ala (OR 0.73, <italic>P </italic>= 0.004), <italic>ADIPOQ </italic>-11,377C&#x0003e;G (OR = 1.25, <italic>P </italic>= 0.015), <italic>ENPP1 </italic>K121Q (OR = 1.30, <italic>P </italic>= 0.003) and <italic>TCF7L2 </italic>rs7903146 (OR = 1.30, <italic>P </italic>= 1.1 &#x000d7; 10<sup>-4</sup>) (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>We did not find evidence for increased T2D risk for <italic>GCK </italic>-30G&#x0003e;A (OR = 1.15, <italic>P </italic>= 0.12), <italic>ADIPOQ </italic>-11,391G&#x0003e;A (OR = 1.07, <italic>P </italic>= 0.58), <italic>HNF1A </italic>I27L (OR = 0.96, <italic>P </italic>= 0.53), <italic>HNF4A </italic>variants rs1884614 (OR = 1.05, <italic>P </italic>= 0.54) and rs2144908 (OR = 1.04, <italic>P </italic>= 0.63), <italic>KCNJ11 </italic>E23K (OR = 0.96, <italic>P </italic>= 0.68), or <italic>SLC30A8 </italic>R325W (OR = 0.95, <italic>P </italic>= 0.44) amongst obese subjects.</p></sec><sec><title>Genotypic heterogeneity</title><p>Discrepancies in genotypic distribution were assessed by Woolf test between the obese and non-obese categories (Table <xref ref-type="table" rid="T3">3</xref>). A genotypic heterogeneity was found for <italic>TCF7L2 </italic>rs7903146 (<italic>P </italic>= 3.2 &#x000d7; 10<sup>-5</sup>) and <italic>ENPP1 </italic>K121Q (<italic>P </italic>= 0.02). Their association with BMI change was then assessed in all studied subgroups. Significant effects on BMI were only detected in the T2D group for the <italic>TCF7L2 </italic>genetic variant [see Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>]. Trends towards heterogeneity were found for <italic>ADIPOQ </italic>11377C&#x0003e;G (<italic>P </italic>= 0.07) and <italic>HNF1A </italic>I27L (<italic>P </italic>= 0.06).</p></sec></sec><sec><title>Discussion</title><p>This large case-control study further supports the hypothesis that the T2D risk contribution of <italic>ENPP1</italic>, <italic>ADIPOQ</italic>, <italic>PPARG </italic>and <italic>TCF7L2 </italic>SNPs may be modulated by obesity status [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Notably, we made the novel finding that T2D risk, as conferred by <italic>HNF1A</italic>, <italic>GCK</italic>, and <italic>SLC30A8 </italic>genetic variants, may also be modified in the presence/absence of obesity. Despite the stringent standards exacted by the Woolf test, genotypic heterogeneity between obese and non-obese individuals was detected for <italic>TCF7L2 </italic>rs7903146 and <italic>ENPP1 </italic>K121Q, and suggested for <italic>ADIPOQ </italic>11377C&#x0003e;G and <italic>HNF1A </italic>I27L SNPs. Future study designs containing more individuals will be needed to confirm all apparent genotypic heterogeneities.</p><p>The analysis of <italic>HNF4A</italic>, <italic>KCNJ11 </italic>and <italic>RETN </italic>polymorphisms did not support their role as T2D risk factors despite sufficient statistical power [see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>] to detect the effect sizes (1.08, 1.09 and 1.16, respectively) previously established by meta-analysis [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. The inability of the current study to replicate previous findings is likely the result of true but modest contributions to T2D risk in the European population.</p><p>While it is known that defects in insulin action and insulin secretion are critical in T2D pathogenesis, their interaction with genetic and environmental factors is less clear. Interestingly, <italic>SLC30A8</italic>, <italic>GCK</italic>, and <italic>HNF1A </italic>genetic variants, all of which have been associated with insulin secretion [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>], were only associated with T2D in non-obese individuals. The <italic>TCF7L2 </italic>genetic variant, another SNP modulating beta cell function [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B36">36</xref>], was more associated with T2D in non-obese subjects than in obese individuals. Conversely, insulin resistance associated genetic variants of <italic>PPARG</italic>, <italic>ADIPOQ </italic>and <italic>ENPP1 </italic>[<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>] were found to be only associated in obese subjects. While obesity has been strongly associated with increased insulin resistance [<xref ref-type="bibr" rid="B3">3</xref>], our data suggests that insulin secretory variants confer a greater T2D risk in non-obese individuals while insulin sensitivity variants more significantly modulate T2D risk in obese subjects.</p><p>Currently, some dissension exists regarding the BMI modulation of the Pro12Ala SNP in T2D risk. Contrary to what was reported by Ghoussaini and colleagues [<xref ref-type="bibr" rid="B11">11</xref>], other studies of the <italic>PPARG </italic>Pro12Ala SNP suggest that the protective effect of the Ala allele may be greater when control BMI is lower [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The present analysis was specifically designed to detect interactions by analyzing a large number of European subjects with no genotypic heterogeneity and characterized by a wide range of BMI. In the "Diabetes Prevention Program", 55 percent of participants were Caucasian, 45 percent were minorities, most were obese, and most had a family history of T2D [<xref ref-type="bibr" rid="B12">12</xref>]. Similarly, Ludivico and colleagues performed a combined analysis of Asian, North American, and European populations. Interestingly, the genetic effect on T2D was found to be ~30% stronger in Asians than in the two other more corpulent populations [<xref ref-type="bibr" rid="B13">13</xref>]. We therefore suggest that population heterogeneity may be the primary contributor to the overall observed BMI effect as supported by the ability of BMI to statistically explain the heterogeneity between these populations but not within Europeans [<xref ref-type="bibr" rid="B13">13</xref>]. Large ethnically-matched studies would be necessary to know if such interaction is found in non-European subjects.</p><p>These results illustrate the importance of BMI in population design as obesity mediated T2D associations may account for part of the difficulty encountered in replication studies. The <italic>ENPP1 </italic>K121Q variant may be illustrative of this point. Studies exploring the T2D risk contribution of the K121Q SNP amongst obese individuals [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>] have found an enhanced association in this subgroup. In the present study, we supported these results in finding no significant effect on T2D in non-obese individuals (OR = 0.99, <italic>P </italic>= 0.94), an association with T2D in obese subjects (OR = 1.30, <italic>P </italic>= 0.003) and a subsequent modest effect when obese and non-obese samples were analyzed together (OR = 1.15, <italic>P </italic>= 0.01). A portion of the heterogeneity amongst previous replication studies may be due to a variable fraction of obese subjects in study designs [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. Considering these results, future association studies should take into account obesity status when interpreting their data.</p><p>A representation of the possible relationship between T2D risk variants and obesity status is modeled in Figure <xref ref-type="fig" rid="F1">1</xref>. This study suggests that the magnitude of a variant's effect on T2D susceptibility is modulated by both obesity status and SNP function. Specifically, variants effecting insulin action more significantly increase T2D susceptibility in obese individuals while variants effecting insulin secretion confer greater T2D risk in non-obese individuals. In our study, data on waist/hip ratio were not available in most T2D cases. However, further analyses of the issue should consider this anthropometric parameter when analyzing interactions between obesity and T2D.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Functional relevance of genetic variants may affect their association with T2D by obesity status</bold>. The present figure does not take into account variants associated with T2D through their effect on BMI.</p></caption><graphic xlink:href="1471-2350-9-45-1"/></fig><p>These data are concordant with results from previous epidemiological and physiological studies. Prospective data indicates that impaired beta cell function, not insulin resistance, predicts future T2D in non-obese subjects [<xref ref-type="bibr" rid="B41">41</xref>]. Furthermore, it was recently reported that interactions between <italic>TCF7L2 </italic>genetic variants and adiposity may lead to reduced beta-cell compensation in leaner individuals but facilitate improved compensation in more obese subjects [<xref ref-type="bibr" rid="B42">42</xref>]. Increased beta-cell mass has indeed been observed in the pancreata of obese compared to lean non-diabetic subjects [<xref ref-type="bibr" rid="B43">43</xref>]. These results support a primary role of insulin secretory modulating variants in the absence of obesity. Conversely, the hyperbolic relationship of insulin resistance and insulin secretion enables the beta-cell to adequately maintain glucose homeostasis for a large range of insulin resistance levels [<xref ref-type="bibr" rid="B44">44</xref>]. In non-obese subjects not affected by adiposity-induced insulin resistance, this mechanism may sufficiently compensate the effects of genetic variants increasing insulin resistance.</p><p>Obesity-induced insulin resistance is characterized by a series of events: i) impaired regulation of lipolysis in adipocytes, ii) increased circulating levels of free fatty acids [<xref ref-type="bibr" rid="B45">45</xref>], iii) ectopic fat storage in muscle and liver, iv) impaired ability of insulin to inhibit hepatic glucose production and muscular glucose uptake [<xref ref-type="bibr" rid="B46">46</xref>], v) increased beta cell death by apoptosis (glucolipotoxicity) [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B47">47</xref>]. In obesity-prone populations, insulin resistance more accurately predicts development of T2D than does insulin secretory dysfunction [<xref ref-type="bibr" rid="B48">48</xref>]. Previous studies on lipodistrophy in both human and murine models have shown that adipose tissue plays a key role in insulin resistance [<xref ref-type="bibr" rid="B49">49</xref>]. Interestingly, <italic>PPARG</italic>, <italic>ADIPOQ</italic>, and <italic>ENPP1 </italic>SNPs only associated with T2D in obese subjects, and have a pivotal role in adipocyte differentiation, maturation, and action [<xref ref-type="bibr" rid="B50">50</xref>-<xref ref-type="bibr" rid="B52">52</xref>]. The effects of genetic polymorphisms leading to insulin resistance may therefore be worsened by obesity.</p><p>In the present study, we suggested that the genetic architecture of T2D may be different in obese and non-obese individuals. In a given ethnic group, the lack of replication in association studies may be, in part, due to different fractions of obesity in case-control designs. Novel SNPs recently identified in genome-wide association studies will prove important in the confirmation of these findings once their functions have been reliably demonstrated.</p></sec><sec><title>Abbreviations</title><p>T2D: Type 2 Diabetes; NG: Normoglycemic; BMI: Body Mass Index; OR: Odds ratio; SNP: Single Nucleotide Polymorphism.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SC managed the study, carried out the genetic analyses and drafted the manuscript. KTN carried out the genetic analyses, drafted the manuscript and carried out the genotyping experiments. HC carried out the genotyping experiments. FH participated in the design of the study. NP participated in the design of the database. BB participated in the design of the study. MM participated in the design of the study. GC participated in the design of the study. PF coordinated the study. DM conceived the study, and participated in its design and coordination. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/9/45/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Supplementary table 1. Homogeneity in genotypic distributions between Swiss and French subjects</p></caption><media xlink:href="1471-2350-9-45-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Supplementary table 2. Hardy-Weinberg equilibrium for each studied SNP</p></caption><media xlink:href="1471-2350-9-45-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Supplementary table 3. Minimum detectable effect size with a statistical power of 80%.</p></caption><media xlink:href="1471-2350-9-45-S3.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p>Supplementary table 4. BMI distribution by <italic>ENPP1 </italic>and <italic>TCF7L2 </italic>genotypes.</p></caption><media xlink:href="1471-2350-9-45-S4.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was partly supported by the French Governmental "<italic>Agence Nationale de la Recherche</italic>", and the charities: "<italic>Association Fran&#x000e7;aise des Diab&#x000e9;tiques" </italic>and "<italic>Programme national de recherche sur le diab&#x000e8;te</italic>". We thank Marianne Deweider and Frederic Allegaert for the DNA bank management and Stefan Gaget for his help on phenotype databases. We are indebted to all subjects who participated to this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>van Haeften</surname><given-names>TW</given-names></name></person-group><article-title>Type 2 diabetes: principles of pathogenesis and therapy</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1333</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">15823385</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)61032-X</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Bowman</surname><given-names>BA</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name><name><surname>Vinicor</surname><given-names>F</given-names></name><name><surname>Bales</surname><given-names>VS</given-names></name><name><surname>Marks</surname><given-names>JS</given-names></name></person-group><article-title>Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001</article-title><source>Jama</source><year>2003</year><volume>289</volume><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">12503980</pub-id><pub-id pub-id-type="doi">10.1001/jama.289.1.76</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Hull</surname><given-names>RL</given-names></name><name><surname>Utzschneider</surname><given-names>KM</given-names></name></person-group><article-title>Mechanisms linking obesity to insulin resistance and type 2 diabetes</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>840</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">17167471</pub-id><pub-id pub-id-type="doi">10.1038/nature05482</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAteer</surname><given-names>JB</given-names></name><name><surname>Prudente</surname><given-names>S</given-names></name><name><surname>Bacci</surname><given-names>S</given-names></name><name><surname>Lyon</surname><given-names>HN</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Trischitta</surname><given-names>V</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name></person-group><article-title>The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>1125</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">18071025</pub-id><pub-id pub-id-type="doi">10.2337/db07-1336</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Urhammer</surname><given-names>SA</given-names></name><name><surname>Ek</surname><given-names>J</given-names></name><name><surname>Albrechtsen</surname><given-names>A</given-names></name><name><surname>Glumer</surname><given-names>C</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Jorgensen</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group><article-title>Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2097</fpage><lpage>2104</lpage><pub-id pub-id-type="pmid">16865358</pub-id><pub-id pub-id-type="doi">10.1007/s00125-006-0353-x</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasseur</surname><given-names>F</given-names></name><name><surname>Helbecque</surname><given-names>N</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Lobbens</surname><given-names>S</given-names></name><name><surname>Delannoy</surname><given-names>V</given-names></name><name><surname>Gaget</surname><given-names>S</given-names></name><name><surname>Boutin</surname><given-names>P</given-names></name><name><surname>Vaxillaire</surname><given-names>M</given-names></name><name><surname>Lepretre</surname><given-names>F</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Bihain</surname><given-names>B</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2607</fpage><lpage>2614</lpage><pub-id pub-id-type="pmid">12354786</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.21.2607</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>S</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Gutierrez-Aguilar</surname><given-names>R</given-names></name><name><surname>Capel</surname><given-names>F</given-names></name><name><surname>Grau</surname><given-names>K</given-names></name><name><surname>Proenca</surname><given-names>C</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Duval</surname><given-names>A</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Potoczna</surname><given-names>N</given-names></name><name><surname>Langin</surname><given-names>D</given-names></name><name><surname>Horber</surname><given-names>F</given-names></name><name><surname>Sorensen</surname><given-names>TI</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Effects of TCF7L2 Polymorphisms on Obesity in European Populations</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>16</volume><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">18239663</pub-id><pub-id pub-id-type="doi">10.1038/oby.2007.77</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Bouatia-Naji</surname><given-names>N</given-names></name><name><surname>Tounian</surname><given-names>A</given-names></name><name><surname>Samson</surname><given-names>C</given-names></name><name><surname>Lecoeur</surname><given-names>C</given-names></name><name><surname>Vatin</surname><given-names>V</given-names></name><name><surname>Ghoussaini</surname><given-names>M</given-names></name><name><surname>Wachter</surname><given-names>C</given-names></name><name><surname>Hercberg</surname><given-names>S</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Patsch</surname><given-names>W</given-names></name><name><surname>Pattou</surname><given-names>F</given-names></name><name><surname>Charles</surname><given-names>MA</given-names></name><name><surname>Tounian</surname><given-names>P</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Jouret</surname><given-names>B</given-names></name><name><surname>Weill</surname><given-names>J</given-names></name><name><surname>Maddux</surname><given-names>BA</given-names></name><name><surname>Goldfine</surname><given-names>ID</given-names></name><name><surname>Walley</surname><given-names>A</given-names></name><name><surname>Boutin</surname><given-names>P</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>863</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">16025115</pub-id><pub-id pub-id-type="doi">10.1038/ng1604</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasseur</surname><given-names>F</given-names></name><name><surname>Helbecque</surname><given-names>N</given-names></name><name><surname>Lobbens</surname><given-names>S</given-names></name><name><surname>Vasseur-Delannoy</surname><given-names>V</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Boutin</surname><given-names>P</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><fpage>892</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15830179</pub-id><pub-id pub-id-type="doi">10.1007/s00125-005-1729-z</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bochenski</surname><given-names>J</given-names></name><name><surname>Placha</surname><given-names>G</given-names></name><name><surname>Wanic</surname><given-names>K</given-names></name><name><surname>Malecki</surname><given-names>M</given-names></name><name><surname>Sieradzki</surname><given-names>J</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>2626</fpage><lpage>2630</lpage><pub-id pub-id-type="pmid">16936213</pub-id><pub-id pub-id-type="doi">10.2337/db06-0191</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghoussaini</surname><given-names>M</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Lobbens</surname><given-names>S</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Charles</surname><given-names>MA</given-names></name><name><surname>Tauber</surname><given-names>M</given-names></name><name><surname>Weill</surname><given-names>J</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population</article-title><source>BMC Med Genet</source><year>2005</year><volume>6</volume><fpage>11</fpage><pub-id pub-id-type="pmid">15784141</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-6-11</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Sun</surname><given-names>MW</given-names></name><name><surname>Bayley</surname><given-names>N</given-names></name><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Shamoon</surname><given-names>H</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>1502</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">17213274</pub-id><pub-id pub-id-type="doi">10.1210/jc.2006-2275</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludovico</surname><given-names>O</given-names></name><name><surname>Pellegrini</surname><given-names>F</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Minenna</surname><given-names>A</given-names></name><name><surname>Mastroianno</surname><given-names>S</given-names></name><name><surname>Cardellini</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>MA</given-names></name><name><surname>Andreozzi</surname><given-names>F</given-names></name><name><surname>Vaccaro</surname><given-names>O</given-names></name><name><surname>Sesti</surname><given-names>G</given-names></name><name><surname>Trischitta</surname><given-names>V</given-names></name></person-group><article-title>Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk</article-title><source>Obesity (Silver Spring)</source><year>2007</year><volume>15</volume><fpage>1076</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">17495182</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deeb</surname><given-names>SS</given-names></name><name><surname>Fajas</surname><given-names>L</given-names></name><name><surname>Nemoto</surname><given-names>M</given-names></name><name><surname>Pihlajamaki</surname><given-names>J</given-names></name><name><surname>Mykkanen</surname><given-names>L</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>W</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity</article-title><source>Nat Genet</source><year>1998</year><volume>20</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">9806549</pub-id><pub-id pub-id-type="doi">10.1038/3099</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Waki</surname><given-names>H</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Tsuboyama-Kasaoka</surname><given-names>N</given-names></name><name><surname>Ezaki</surname><given-names>O</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Gavrilova</surname><given-names>O</given-names></name><name><surname>Vinson</surname><given-names>C</given-names></name><name><surname>Reitman</surname><given-names>ML</given-names></name><name><surname>Kagechika</surname><given-names>H</given-names></name><name><surname>Shudo</surname><given-names>K</given-names></name><name><surname>Yoda</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">11479627</pub-id><pub-id pub-id-type="doi">10.1038/90984</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maddux</surname><given-names>BA</given-names></name><name><surname>Goldfine</surname><given-names>ID</given-names></name></person-group><article-title>Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">10615944</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.49.1.13</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Lupi</surname><given-names>R</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><name><surname>Del Guerra</surname><given-names>S</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Sjogren</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Eriksson</surname><given-names>KF</given-names></name><name><surname>Lethagen</surname><given-names>AL</given-names></name><name><surname>Mancarella</surname><given-names>R</given-names></name><name><surname>Berglund</surname><given-names>G</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Del Prato</surname><given-names>S</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>2155</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">17671651</pub-id><pub-id pub-id-type="doi">10.1172/JCI30706</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steppan</surname><given-names>CM</given-names></name><name><surname>Bailey</surname><given-names>ST</given-names></name><name><surname>Bhat</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Banerjee</surname><given-names>RR</given-names></name><name><surname>Wright</surname><given-names>CM</given-names></name><name><surname>Patel</surname><given-names>HR</given-names></name><name><surname>Ahima</surname><given-names>RS</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>The hormone resistin links obesity to diabetes</article-title><source>Nature</source><year>2001</year><volume>409</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">11201732</pub-id><pub-id pub-id-type="doi">10.1038/35053000</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>EM</given-names></name><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Carstensen</surname><given-names>B</given-names></name><name><surname>Echwald</surname><given-names>SM</given-names></name><name><surname>Drivsholm</surname><given-names>T</given-names></name><name><surname>Glumer</surname><given-names>C</given-names></name><name><surname>Thorsteinsson</surname><given-names>B</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group><article-title>The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">12540638</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.52.2.573</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehto</surname><given-names>M</given-names></name><name><surname>Bitzen</surname><given-names>PO</given-names></name><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Wipemo</surname><given-names>C</given-names></name><name><surname>Wessman</surname><given-names>Y</given-names></name><name><surname>Forsblom</surname><given-names>C</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>423</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">10334325</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.48.2.423</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>S</given-names></name><name><surname>Raeder</surname><given-names>H</given-names></name><name><surname>Eide</surname><given-names>SA</given-names></name><name><surname>Midthjell</surname><given-names>K</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Sovik</surname><given-names>O</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Njolstad</surname><given-names>PR</given-names></name></person-group><article-title>Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the hepatocyte nuclear factor 4 alpha (HNF4A) P2 region are associated with type 2 diabetes in Scandinavians</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>3112</fpage><lpage>3117</lpage><pub-id pub-id-type="pmid">17827402</pub-id><pub-id pub-id-type="doi">10.2337/db07-0513</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmkvist</surname><given-names>J</given-names></name><name><surname>Cervin</surname><given-names>C</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Anevski</surname><given-names>D</given-names></name><name><surname>Cilio</surname><given-names>C</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Berglund</surname><given-names>G</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Common variants in HNF-1 alpha and risk of type 2 diabetes</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2882</fpage><lpage>2891</lpage><pub-id pub-id-type="pmid">17033837</pub-id><pub-id pub-id-type="doi">10.1007/s00125-006-0450-x</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Takamoto</surname><given-names>I</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Matsui</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Komeda</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>A</given-names></name><name><surname>Toyoda</surname><given-names>Y</given-names></name><name><surname>Miwa</surname><given-names>I</given-names></name><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Tsubamoto</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">17200721</pub-id><pub-id pub-id-type="doi">10.1172/JCI17645</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Velho</surname><given-names>G</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Pueyo</surname><given-names>ME</given-names></name><name><surname>Rakotoambinina</surname><given-names>B</given-names></name><name><surname>Zouali</surname><given-names>H</given-names></name><name><surname>Passa</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Robert</surname><given-names>JJ</given-names></name></person-group><article-title>Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young</article-title><source>Lancet</source><year>1992</year><volume>340</volume><fpage>444</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">1354782</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(92)91768-4</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Reynisdottir</surname><given-names>I</given-names></name><name><surname>Benediktsson</surname><given-names>R</given-names></name><name><surname>Jonsdottir</surname><given-names>T</given-names></name><name><surname>Walters</surname><given-names>GB</given-names></name><name><surname>Styrkarsdottir</surname><given-names>U</given-names></name><name><surname>Gretarsdottir</surname><given-names>S</given-names></name><name><surname>Emilsson</surname><given-names>V</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Snorradottir</surname><given-names>S</given-names></name><name><surname>Bjarnason</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>MC</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Bagger</surname><given-names>Y</given-names></name><name><surname>Wilensky</surname><given-names>RL</given-names></name><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lashley</surname><given-names>K</given-names></name><name><surname>Doumatey</surname><given-names>A</given-names></name><name><surname>So</surname><given-names>WY</given-names></name><name><surname>Ma</surname><given-names>RC</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>A variant in CDKAL1 influences insulin response and risk of type 2 diabetes</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>770</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">17460697</pub-id><pub-id pub-id-type="doi">10.1038/ng2043</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osawa</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Onuma</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Ochi</surname><given-names>M</given-names></name><name><surname>Kawata</surname><given-names>H</given-names></name><name><surname>Nishimiya</surname><given-names>T</given-names></name><name><surname>Niiya</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>I</given-names></name><name><surname>Nishida</surname><given-names>W</given-names></name><name><surname>Hashiramoto</surname><given-names>M</given-names></name><name><surname>Kanatsuka</surname><given-names>A</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name></person-group><article-title>The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><fpage>678</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">15338456</pub-id><pub-id pub-id-type="doi">10.1086/424761</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Dam</surname><given-names>RM</given-names></name><name><surname>Hoebee</surname><given-names>B</given-names></name><name><surname>Seidell</surname><given-names>JC</given-names></name><name><surname>Schaap</surname><given-names>MM</given-names></name><name><surname>de Bruin</surname><given-names>TW</given-names></name><name><surname>Feskens</surname><given-names>EJ</given-names></name></person-group><article-title>Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">15842514</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-5491.2005.01465.x</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Owen</surname><given-names>KR</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><name><surname>Hitman</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Love-Gregory</surname><given-names>LD</given-names></name><name><surname>Permutt</surname><given-names>MA</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name></person-group><article-title>Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the U.K. population</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>3002</fpage><lpage>3006</lpage><pub-id pub-id-type="pmid">15504983</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.53.11.3002</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Holmkvist</surname><given-names>J</given-names></name><name><surname>Cervin</surname><given-names>C</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Gaudet</surname><given-names>D</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Association of common variation in the HNF1alpha gene region with risk of type 2 diabetes</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2336</fpage><lpage>2342</lpage><pub-id pub-id-type="pmid">16046299</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.54.8.2336</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Gaudet</surname><given-names>D</given-names></name><name><surname>Bostrom</surname><given-names>KB</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Hitman</surname><given-names>G</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">17327436</pub-id><pub-id pub-id-type="doi">10.2337/db06-0202</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkau</surname><given-names>B</given-names></name></person-group><article-title>[An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]</article-title><source>Rev Epidemiol Sante Publique</source><year>1996</year><volume>44</volume><fpage>373</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">8927780</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sladek</surname><given-names>R</given-names></name><name><surname>Rocheleau</surname><given-names>G</given-names></name><name><surname>Rung</surname><given-names>J</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Serre</surname><given-names>D</given-names></name><name><surname>Boutin</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>D</given-names></name><name><surname>Belisle</surname><given-names>A</given-names></name><name><surname>Hadjadj</surname><given-names>S</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Heude</surname><given-names>B</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Posner</surname><given-names>BI</given-names></name><name><surname>Balding</surname><given-names>DJ</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Polychronakos</surname><given-names>C</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>A genome-wide association study identifies novel risk loci for type 2 diabetes</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">17293876</pub-id><pub-id pub-id-type="doi">10.1038/nature05616</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinds</surname><given-names>DA</given-names></name><name><surname>Stuve</surname><given-names>LL</given-names></name><name><surname>Nilsen</surname><given-names>GB</given-names></name><name><surname>Halperin</surname><given-names>E</given-names></name><name><surname>Eskin</surname><given-names>E</given-names></name><name><surname>Ballinger</surname><given-names>DG</given-names></name><name><surname>Frazer</surname><given-names>KA</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>Whole-genome patterns of common DNA variation in three human populations</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1072</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">15718463</pub-id><pub-id pub-id-type="doi">10.1126/science.1105436</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Branson</surname><given-names>R</given-names></name><name><surname>Potoczna</surname><given-names>N</given-names></name><name><surname>Kral</surname><given-names>JG</given-names></name><name><surname>Lentes</surname><given-names>KU</given-names></name><name><surname>Hoehe</surname><given-names>MR</given-names></name><name><surname>Horber</surname><given-names>FF</given-names></name></person-group><article-title>Binge eating as a major phenotype of melanocortin 4 receptor gene mutations</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1096</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">12646666</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa021971</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silander</surname><given-names>K</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Peck</surname><given-names>EC</given-names></name><name><surname>Hollstein</surname><given-names>P</given-names></name><name><surname>Skol</surname><given-names>AD</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Stavrides</surname><given-names>G</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Conneely</surname><given-names>KN</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Fingerlin</surname><given-names>TE</given-names></name><name><surname>Dhanjal</surname><given-names>SK</given-names></name><name><surname>Valle</surname><given-names>TT</given-names></name><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>RM</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name></person-group><article-title>Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">15047633</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.53.4.1141</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlgren</surname><given-names>A</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>Jensevik</surname><given-names>K</given-names></name><name><surname>Syvanen</surname><given-names>AC</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name></person-group><article-title>Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men</article-title><source>Diabetologia</source><year>2007</year><pub-id pub-id-type="pmid">17618413</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Vozarova</surname><given-names>B</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Weyer</surname><given-names>C</given-names></name><name><surname>Lindsay</surname><given-names>RS</given-names></name><name><surname>Youngren</surname><given-names>JF</given-names></name><name><surname>Havel</surname><given-names>PJ</given-names></name><name><surname>Pratley</surname><given-names>RE</given-names></name><name><surname>Bogardus</surname><given-names>C</given-names></name><name><surname>Tataranni</surname><given-names>PA</given-names></name></person-group><article-title>Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>1884</fpage><lpage>1888</lpage><pub-id pub-id-type="pmid">12031977</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.6.1884</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubaszek</surname><given-names>A</given-names></name><name><surname>Pihlajamaki</surname><given-names>J</given-names></name><name><surname>Karhapaa</surname><given-names>P</given-names></name><name><surname>Vauhkonen</surname><given-names>I</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group><article-title>The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>464</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">12547881</pub-id><pub-id pub-id-type="doi">10.2337/diacare.26.2.464</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>S</given-names></name><name><surname>Ludovico</surname><given-names>O</given-names></name><name><surname>Prudente</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Mangiacotti</surname><given-names>D</given-names></name><name><surname>Rauseo</surname><given-names>A</given-names></name><name><surname>Nolan</surname><given-names>D</given-names></name><name><surname>Duffy</surname><given-names>J</given-names></name><name><surname>Fini</surname><given-names>G</given-names></name><name><surname>Salvemini</surname><given-names>L</given-names></name><name><surname>Amico</surname><given-names>C</given-names></name><name><surname>Vigna</surname><given-names>C</given-names></name><name><surname>Pellegrini</surname><given-names>F</given-names></name><name><surname>Menzaghi</surname><given-names>C</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Trischitta</surname><given-names>V</given-names></name></person-group><article-title>The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>3021</fpage><lpage>3025</lpage><pub-id pub-id-type="pmid">16186408</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.54.10.3021</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><name><surname>Hitman</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name></person-group><article-title>No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>3175</fpage><lpage>3179</lpage><pub-id pub-id-type="pmid">17065358</pub-id><pub-id pub-id-type="doi">10.2337/db06-0410</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvarsson</surname><given-names>M</given-names></name><name><surname>Wajngot</surname><given-names>A</given-names></name><name><surname>Cerasi</surname><given-names>E</given-names></name><name><surname>Efendic</surname><given-names>S</given-names></name></person-group><article-title>K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><fpage>2262</fpage><lpage>2268</lpage><pub-id pub-id-type="pmid">16160865</pub-id><pub-id pub-id-type="doi">10.1007/s00125-005-1929-6</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>RM</given-names></name><name><surname>Allayee</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>AH</given-names></name><name><surname>Trigo</surname><given-names>E</given-names></name><name><surname>Hartiala</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>JM</given-names></name><name><surname>Buchanan</surname><given-names>TA</given-names></name></person-group><article-title>Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1481</fpage><lpage>1485</lpage><pub-id pub-id-type="pmid">17317761</pub-id><pub-id pub-id-type="doi">10.2337/db06-1682</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>AE</given-names></name><name><surname>Janson</surname><given-names>J</given-names></name><name><surname>Bonner-Weir</surname><given-names>S</given-names></name><name><surname>Ritzel</surname><given-names>R</given-names></name><name><surname>Rizza</surname><given-names>RA</given-names></name><name><surname>Butler</surname><given-names>PC</given-names></name></person-group><article-title>Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12502499</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.52.1.102</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>H</given-names></name><name><surname>Ahren</surname><given-names>B</given-names></name></person-group><article-title>Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>650</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">10834425</pub-id><pub-id pub-id-type="doi">10.2337/diacare.23.5.650</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>Role of fatty acids in the pathogenesis of insulin resistance and NIDDM</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">8971073</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.46.1.3</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltiel</surname><given-names>AR</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name></person-group><article-title>Insulin signalling and the regulation of glucose and lipid metabolism</article-title><source>Nature</source><year>2001</year><volume>414</volume><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">11742412</pub-id><pub-id pub-id-type="doi">10.1038/414799a</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Nolan</surname><given-names>CJ</given-names></name></person-group><article-title>Islet beta cell failure in type 2 diabetes</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1802</fpage><lpage>1812</lpage><pub-id pub-id-type="pmid">16823478</pub-id><pub-id pub-id-type="doi">10.1172/JCI29103</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lillioja</surname><given-names>S</given-names></name><name><surname>Mott</surname><given-names>DM</given-names></name><name><surname>Spraul</surname><given-names>M</given-names></name><name><surname>Ferraro</surname><given-names>R</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Bennett</surname><given-names>PH</given-names></name><name><surname>Bogardus</surname><given-names>C</given-names></name></person-group><article-title>Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>1988</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">8247074</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199312303292703</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>A</given-names></name></person-group><article-title>Lipodystrophies</article-title><source>Am J Med</source><year>2000</year><volume>108</volume><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">11126308</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(99)00414-3</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Crowley</surname><given-names>VE</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name><name><surname>Soos</surname><given-names>MA</given-names></name><name><surname>Maslen</surname><given-names>GL</given-names></name><name><surname>Williams</surname><given-names>TD</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Schafer</surname><given-names>AJ</given-names></name><name><surname>Chatterjee</surname><given-names>VK</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name></person-group><article-title>Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10622252</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Minokoshi</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Waki</surname><given-names>H</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Kita</surname><given-names>S</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Foufelle</surname><given-names>F</given-names></name><name><surname>Ferre</surname><given-names>P</given-names></name><name><surname>Carling</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Kahn</surname><given-names>BB</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>1288</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">12368907</pub-id><pub-id pub-id-type="doi">10.1038/nm788</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Ciociola</surname><given-names>E</given-names></name><name><surname>Chandalia</surname><given-names>M</given-names></name><name><surname>Abate</surname><given-names>N</given-names></name></person-group><article-title>Role of ENPP1 on adipocyte maturation</article-title><source>PLoS ONE</source><year>2007</year><volume>2</volume><fpage>e882</fpage><pub-id pub-id-type="pmid">17849011</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000882</pub-id></citation></ref></ref-list></back></article> 